Source: http://www.google.com/patents/US7829120?dq=%22Meaning-based+information+organization+and+retrieval%22
Timestamp: 2015-05-25 02:20:58
Document Index: 534057051

Matched Legal Cases: ['Application No. 2186', 'Application No. 2187', 'Application No. 2187', 'Application No. 600', 'Application No. 605', 'Application No. 605']

Patent US7829120 - Trazodone composition for once a day administration - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inAdvanced Patent SearchPatentsThe invention relates to a once a day formulation of trazodone or a trazodone derivative. The formulation contains trazodone or a trazodone derivative and a controlled release excipient so that, once administered orally, the trazodone or the trazodone derivative is maintained at a therapeutic plasma...http://www.google.com/patents/US7829120?utm_source=gb-gplus-sharePatent US7829120 - Trazodone composition for once a day administrationAdvanced Patent SearchPublication numberUS7829120 B2Publication typeGrantApplication numberUS 11/519,194Publication dateNov 9, 2010Filing dateSep 11, 2006Priority dateSep 9, 2005Fee statusPaidAlso published asCA2616204A1, CA2616416A1, CN101242856A, CN101252932A, CN101252932B, EP1931346A2, EP1931346A4, EP1931346B1, EP1940467A2, EP1940467A4, US8414919, US8795723, US8962019, US20070128269, US20070128275, US20110015205, US20110021535, US20110027370, US20110033537, WO2007048219A2, WO2007048219A3, WO2007048220A2, WO2007048220A3Publication number11519194, 519194, US 7829120 B2, US 7829120B2, US-B2-7829120, US7829120 B2, US7829120B2InventorsSonia Gervais, Damon Smith, Miloud Rahmouni, Pauline Contamin, Rachid Ouzerourou, My Linh Ma, Angela Ferrada, Fouzia SoulhiOriginal AssigneeLabopharm Inc., Labopharm Europe Limited, Labopharm (Barbados) LimitedExport CitationBiBTeX, EndNote, RefManPatent Citations (114), Non-Patent Citations (38), Referenced by (1), Classifications (20), Legal Events (6) External Links: USPTO, USPTO Assignment, EspacenetTrazodone composition for once a day administration
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS2987445Oct 10, 1958Jun 6, 1961Rohm & HaasDrug compositionUS3087860Dec 19, 1958Apr 30, 1963Abbott LabMethod of prolonging release of drug from a precompressed solid carrierUS3336200Oct 1, 1963Aug 15, 1967Warner Lambert PharmaceuticalTablet structureUS3381009Oct 28, 1966Apr 30, 1968AcrafTriazole-(4,3-a)-pyridinesUS3652589Jul 27, 1967Mar 28, 1972Gruenenthal Chemie1-(m-substituted phenyl)-2-aminomethyl cyclohexanolsUS4131675 *Feb 9, 1978Dec 26, 1978Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.Use of combinations of L-DOPA with trazodone and L-DOPA with etoperidone in ParkinsonismUS4820522Jul 27, 1987Apr 11, 1989Mcneilab, Inc.Oral sustained release acetaminophen formulation and processUS4906632 *Nov 28, 1988Mar 6, 1990Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F.SMethod of preventing myocardial infarction and acute cerebral ischaemiaUS4938968Jul 26, 1988Jul 3, 1990Norjec Development Associates, Inc.Controlled release indomethacinUS4968509Jan 19, 1989Nov 6, 1990Mcneilab, Inc.Oral sustained release acetaminophen formulation and processUS5004613Aug 11, 1989Apr 2, 1991Mcneil-Ppc, Inc.Oral sustained release pharmaceutical formulation and processUS5133974Jan 24, 1990Jul 28, 1992Kv Pharmaceutical CompanyExtended release pharmaceutical formulationsUS5273760Dec 24, 1991Dec 28, 1993Euroceltigue, S.A.Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymerUS5286493Jan 27, 1992Feb 15, 1994Euroceltique, S.A.Stabilized controlled release formulations having acrylic polymer coatingUS5336691Nov 10, 1992Aug 9, 1994Mcneilab, Inc.Composition comprising a tramadol material and acetaminophen and its useUS5407686Jan 29, 1992Apr 18, 1995Sidmak Laboratories, Inc.Sustained release composition for oral administration of active ingredientUS5414129Sep 8, 1993May 9, 1995Chemagis, Ltd.Process for the purification of 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol and its saltsUS5427799Sep 16, 1993Jun 27, 1995Valentine Enterprises, Inc.Sustained release composition and method utilizing xanthan gum and an active ingredientUS5456921Feb 9, 1994Oct 10, 1995Labopharm, Inc.Use of cross-linked amylose as a matrix for the slow release of biologically active compoundsUS5478577Nov 23, 1993Dec 26, 1995Euroceltique, S.A.Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug levelUS5520931Jan 4, 1995May 28, 1996Gacell Laboratories AbControlled release morphine preparationUS5560331Nov 16, 1995Oct 1, 1996Yamaha Hatsudoki Kabushiki KaishaCylinder head for engineUS5562924Mar 10, 1993Oct 8, 1996ColeticaPolysaccharide wall microcapsules containing primary alcohol functions and compositions containing sameUS5580578Jul 27, 1993Dec 3, 1996Euro-Celtique, S.A.Controlled release formulations coated with aqueous dispersions of acrylic polymersUS5591452May 10, 1994Jan 7, 1997Euro-Celtique, S.A.Controlled release formulationUS5595762Nov 30, 1993Jan 21, 1997Laboratoires VirbacStabilized pulverulent active agents, compositions containing them, process for obtaining them and their applicationsUS5601842Jan 16, 1996Feb 11, 1997Gruenenthal GmbhSustained release drug formulation containing a tramadol saltUS5603956Jun 16, 1994Feb 18, 1997Labopharm Inc.Cross-linked enzymatically controlled drug releaseUS5616343Mar 25, 1993Apr 1, 1997Labopharm, Inc.Cross-linked amylose as a binder/disintegrant in tabletsUS5639476Jun 2, 1995Jun 17, 1997Euro-Celtique, S.A.Controlled release formulations coated with aqueous dispersions of acrylic polymersUS5663279Aug 5, 1994Sep 2, 1997Akzo Nobel NvOphthalmic lensesUS5672360Nov 22, 1994Sep 30, 1997Purdue Pharma, L.P.Method of treating pain by administering 24 hour oral opioid formulationsUS5672755Nov 14, 1996Sep 30, 1997Chemagis Ltd.Process for the purification of (RR-SS)-2-dimethyl-aminomethyl-1-(3-methoxyphenyl)cyclohexanol and its saltsUS5681585Jun 20, 1996Oct 28, 1997Euro-Celtique, S.A.Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymerUS5773031Feb 27, 1996Jun 30, 1998L. Perrigo CompanyAcetaminophen sustained-release formulationUS5776492Aug 19, 1996Jul 7, 1998Gruenenthal GmbhRapidly disintegrating medicinal form of tramadol or a tramadol saltUS5780057Feb 14, 1997Jul 14, 1998Jagotec AgPharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluidsUS5807575Feb 14, 1997Sep 15, 1998Rougier Inc.Manufacture of cross-linked amylose useful as a excipient for control release of active compoundsUS5814338Jun 24, 1995Sep 29, 1998Therapicon S.R.L.Drug delivery systemUS5843480Dec 27, 1996Dec 1, 1998Euro-Celtique, S.A.Controlled release diamorphine formulationUS5849240Feb 27, 1996Dec 15, 1998Euro-Celtique, S.A.Method of preparing sustained release pharmaceutical compositionsUS5874620Aug 14, 1997Feb 23, 1999Chemagis, Ltd.Process for the purification of (RR-SS)-2-dimethylaminomethyl-1-(3-methoxyphenyl)cyclohexanol hydrochlorideUS5877351Dec 24, 1997Mar 2, 1999Wyckoff Chemical Company, Inc.Preparation and purification process for 2- (dimethylamino) methyl!-1-(3-methoxphenyl)-cyclohexanol and its saltsUS5879705Apr 18, 1997Mar 9, 1999Euro-Celtique S.A.Sustained release compositions of morphine and a method of preparing pharmaceutical compositionsUS5879707Oct 30, 1996Mar 9, 1999Universite De MontrealSubstituted amylose as a matrix for sustained drug releaseUS5885615Aug 19, 1996Mar 23, 1999Labopharm Inc.Pharmaceutical controlled release tablets containing a carrier made of cross-linked amylose and hydroxypropylmethylcelluloseUS5891471Feb 27, 1996Apr 6, 1999Euro-Celtique, S.A.Pharmaceutical multiparticulatesUS5958459Nov 27, 1995Sep 28, 1999Purdue Pharma L.P.Opioid formulations having extended controlled releasedUS5965163Sep 30, 1997Oct 12, 1999Euro-Celtique, S.A.Substained release compositions and a method of preparing pharmaceutical compositionsUS5968551Jul 27, 1995Oct 19, 1999Purdue Pharma L.P.Orally administrable opioid formulations having extended duration of effectUS5981592Apr 9, 1998Nov 9, 1999Loma Linda University Medical CenterMethod and composition for treating cystic fibrosisUS6103261Jan 6, 1999Aug 15, 2000Purdue Pharma LpOpioid formulations having extended controlled releaseUS6129205Dec 9, 1998Oct 10, 2000Ashworth Bros. Inc.Variable loop count conveyor beltUS6129933Jul 24, 1997Oct 10, 2000Purdue Pharma LpStabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymerUS6143322Apr 8, 1997Nov 7, 2000Purdue Pharma L.P.Method of treating humans with opioid formulations having extended controlled releaseUS6143325 *Apr 26, 1999Nov 7, 2000Bristol-Myers Squibb CompanyNefazodone dosage formUS6143328Mar 8, 1999Nov 7, 2000Euro-Celtique, S.A.Sustained release compositions and a method of preparing pharmaceutical compositionsUS6143353Mar 11, 1997Nov 7, 2000Purdue Pharma LpControlled release formulations coated with aqueous dispersions of acrylic polymersUS6156342May 26, 1998Dec 5, 2000Andex Pharmaceuticals, Inc.Controlled release oral dosage formUS6156343 *Dec 26, 1995Dec 5, 2000Akzo Nobel N.V.Controlled release preparationUS6162467Aug 9, 1999Dec 19, 2000Euro-Celtique, S.A.Sustained release compositions and a method of preparing pharmaceutical compositionsUS6190591 *Oct 27, 1997Feb 20, 2001General Mills, Inc.Embedding and encapsulation of controlled release particlesUS6210714Feb 14, 2000Apr 3, 2001Euro-Celtique S.A.Immediate release tablet cores of acetaminophen having sustained-release coatingUS6211229Feb 17, 2000Apr 3, 2001Neil B. KaveyTreatment of transient and short term insomniaUS6214331Dec 12, 1997Apr 10, 2001C. R. Bard, Inc.Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtainedUS6228875 *Apr 14, 1999May 8, 2001The General Hospital CorporationMethods for treating neuropsychiatric disordersUS6238698Aug 29, 1997May 29, 2001Lts Lohmann Therapie-Systeme GmbhOral preparation containing at least one active pharmaceutical substance in a matrix capable of swelling in an aqueous mediumUS6245357Feb 12, 1999Jun 12, 2001Alza CorporationExtended release dosage formUS6245387Nov 3, 1998Jun 12, 2001Diamon-Fusion International, Inc.Capped silicone film and method of manufacture thereofUS6248363Nov 23, 1999Jun 19, 2001Lipocine, Inc.Solid carriers for improved delivery of active ingredients in pharmaceutical compositionsUS6254881Dec 17, 1997Jul 3, 2001Bimeda Research & Development LimitedAntiinfective free intramammary veterinary compositionUS6254887Jul 10, 1996Jul 3, 2001Euro-Celtique S.A.Controlled release tramadolUS6277887 *Apr 20, 2000Aug 21, 2001Sepracor, Inc.Methods for treating Parkinson's disease using optically pure (−)-bupropionUS6284273Feb 24, 1998Sep 4, 2001Vincent LenaertsCross-linked high amylose starch resistant to amylase as a matrix for the slow release of biologically active compoundsUS6294195Sep 7, 1999Sep 25, 2001Purdue Pharma L.P.Orally administrable opioid formulations having extended duration of effectUS6306438Jul 2, 1998Oct 23, 2001Euro-Celtique, S.A.Stabilized sustained release tramadol formulationsUS6316031Dec 22, 1999Nov 13, 2001Purdue Pharma LpStabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymerUS6326027May 24, 1995Dec 4, 2001Euro-Celtique S.A.Controlled release formulationUS6326404Aug 21, 2000Dec 4, 2001Gruenenthal GmbhUse of O-desmethyl-N-mono-desmethyl-tramadolUS6339105Oct 12, 1999Jan 15, 2002Ortho-Mcneil Pharmaceutical, Inc.Analgesic regimenUS6372255Dec 11, 1998Apr 16, 2002Merck Patent GesellschaftTablet for instant and prolonged release of one or more active substancesUS6387404Feb 6, 2001May 14, 2002Euro-Celtique S.A.Immediate release tablet cores of insoluble drugs having sustained-release coatingUS6399096Sep 30, 1996Jun 4, 2002Euro-Celtique S.A.Pharmaceutical formulationUS6419957 *Feb 24, 1999Jul 16, 2002Labopharm, Inc.Cross-linked high amylose starch having functional groups as a matrix for the slow release of pharmaceutical agentsUS6451350Jan 18, 2000Sep 17, 2002Gruenenthal GmbhControlled release tramadol preparation with a storage-stable release profile and process for their productionUS6569463Mar 6, 2001May 27, 2003Lipocine, Inc.Solid carriers for improved delivery of hydrophobic active ingredients in pharmaceutical compositionsUS6572885Jun 26, 2001Jun 3, 2003Euro-Celtique, S.A.Orally administrable opioid formulations having extended duration of effectUS6576260Feb 28, 2002Jun 10, 2003Gruenenthal GmbhSustained-release form of administration containing tramadol saccharinateUS6586006Jan 5, 2001Jul 1, 2003Elan Drug Delivery LimitedSolid delivery systems for controlled release of molecules incorporated therein and methods of making sameUS6593373Oct 12, 2001Jul 15, 2003Gruenenthal GmbhPharmaceutical compositions of O-desmethyl-N-mono-desmethyl-tramadolUS6607748Jun 29, 2000Aug 19, 2003Vincent LenaertsCross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufactureUS6632640Jul 9, 1999Oct 14, 2003The United States Of America As Represented By The Secretary Of The ArmyVaccine against Staphylococcus intoxicationUS6635279Mar 20, 2001Oct 21, 2003Basf AktiengesellschaftActive ingredient-containing floating forms comprising polyvinyl acetate and polyvinylpyrrolidone, their use and productionUS6645537Feb 13, 2001Nov 11, 2003Keurig, IncorporatedBeverage filter cartridgeUS6659373May 30, 2001Dec 9, 2003L. R. NelsonOne touch actuated valveUS6660774Apr 5, 2002Dec 9, 2003Gruenethal GmbhUse of (+)-tramadol, O-demethyltramadol or (+)-O-demethyl-tramadol, O-desmethyl-N-mono-desmethyl-tramadol or (+)- O-desmethyl-N-mono-desmethyltramadolUS6685964Jan 18, 2000Feb 3, 2004Gruenenthal GmbhOpioid analgesics with controlled active substance releaseUS6723343Feb 28, 2002Apr 20, 2004Gruenenthal GmbhPharmaceutical tramadol saltsUS6733783Oct 30, 2001May 11, 2004Euro-Celtique S.A.Controlled release hydrocodone formulationsUS6743442Feb 6, 2001Jun 1, 2004Euro-Celtique, S.A.Melt-extruded orally administrable opioid formulationsUS6806293Mar 12, 2001Oct 19, 2004Darley Pharmaceuticals LtdUse of pheromone compounds having MAP kinase modulating activityUS6806294Apr 23, 2002Oct 19, 2004Euro-Celtique S.A.Opioid analgesicUS6863901Nov 30, 2001Mar 8, 2005Collegium Pharmaceutical, Inc.Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administrationUS6923988May 1, 2003Aug 2, 2005Lipocine, Inc.Solid carriers for improved delivery of active ingredients in pharmaceutical compositionsUS6962717Jan 29, 1999Nov 8, 2005Disphar International B.V.Pharmaceutical compositionsUS6968551Aug 17, 2001Nov 22, 2005John HedigerSystem and user interface for generation and processing of software application installation instructionsUS7074430Mar 6, 2001Jul 11, 2006Euro-Celtique S.A.Controlled release tramadol tramadol formulationUS20020165246 *Mar 5, 2002Nov 7, 2002Andrew HolmanAdministration of sleep restorative agentsUS20030180362 *Feb 3, 2003Sep 25, 2003Pacific CorporationMulti-stage oral drug controlled-release systemUS20050256131 *May 21, 2003Nov 17, 2005Carl-Fr CoesterPharmaceutical active substance combination and the use thereofUS20060111307 *Nov 16, 2005May 25, 2006Wendye RobbinsMethods and compositions for treating painUS20060172006 *Oct 6, 2004Aug 3, 2006Vincent LenaertsSustained-release tramadol formulations with 24-hour clinical efficacyWO2003099265A2 *May 21, 2003Dec 4, 2003Carl-Fr CoesterPharmaceutical active substance combination and the use thereofWO2004038428A2 *Oct 27, 2003May 6, 2004Jonathan BaconControlled-release compositions* Cited by examinerNon-Patent CitationsReference1Adler, L. et al., "A Comparison of Once-Daily Tramadol with Normal Release Tramadol in the Treatment of Pain in Osteoarthritis, " The Journal of Rheumatology 2002, vol. 29, No. 10, pp. 2196-2199.2Bodalia et al., "A Comparison of the Pharmacokinetics, Clinical Efficacy, and Tolerability of Once-Daily Tramadol Tablets with Normal Release Tramadol Capsules," Journal of Pain and Symptom Management , vol. 25, No. 2, pp. 142-149 (2003).3Boureau, "Tramadol in Post-Herpetic Neuralgia: A Randomized, Double-Blind, Placebo-Controlled Trial," PAIN, Elsevier Sci Pub. 2003, vol. 104 (1/2):323-331.4De Jong (1997) "Comment on the hypoalgesic effect of tramadol in relation to CYP2D6," Pain Dig. 7:245.5Desmeules, "The tramadol option," European Journal of Pain, 4, Suppl. A:15-21 (2000).6Excerpt from "Controlled Drug Delivery. Fundamentals and Applications," Second Edition, Revised and Expanded, Joseph R. Robinson, et al., Editors (1987) (68 pages).7Excerpt from "Handbook of Pharmaceutical Controlled Release Technology," Donald L. Wise, Executive Editor (2000) (80 pages).8Fleischmann, "Tramadol for the treatment of joint pain associated with osteoarthritis: a randomized, double-blind, placebo-controlled trial," Current Therapeutic Research 62(2):113-128 (2001).9Gennaro R. Alfonso, Remington Farmacia, 19th Edition, Panamericana, Spain. 1988, pp. 2470, 2535 (in Spanish) and an English translation.10International Search Report for International Patent Application No. PCT/CA03/01637, dated Apr. 27, 2004.11International Search Report for International Patent Application No. PCT/CA03/01638, dated Apr. 27, 2004.12Klaschik, "Office-oriented pain therapy in cancer patients-Adequate alleviation of pain with the appropriate medication," Klinikarzt 31(9):250-256 (2002). (English abstract provided on p. 256).13Klaschik, "Office-oriented pain therapy in cancer patients—Adequate alleviation of pain with the appropriate medication," Klinikarzt 31(9):250-256 (2002). (English abstract provided on p. 256).14Kogel et al., "Involvement of metabolites in the analgesic action of tramadol," Proc. 9th World Congress on Pain, Vienna, Austria, Aug. 22-27, 1999, pp. 523.15Labopharm. Inc. Press Release dated Feb. 2, 2010 relating to FDA approval of OLEPTRO(TM) (4 pages).16Labopharm. Inc. Press Release dated Feb. 2, 2010 relating to FDA approval of OLEPTRO™ (4 pages).17Mendelson, "A Review of the Evidence for the Efficacy and Safety of Trazodone in Insomnia," J. Clin. Psychiatry 66:4, pp. 469-476 (2005).18Moon et al., "Efficacy and Tolerability of Controlled-Release Trazodone in Depression: A Large Multi-Centre Study in General Practice," Current Med. Res. and Opinion vol. 12, No. 3, pp. 160-168 (1990).19Nies and Spielberg, Goodman & Gilman. Las Bases Farmacologicas de la Terapeutica. Novena Edicion. vol. I. McGraw-Hill. Interamericana. Mexico. 1996, pp. 47, 58 (in Spanish) and an English translation.20Opposition statement against Chilean Application No. 2186-2003 by La Asociacion Industrial De Laboratorios Farmaceuticos A.G. (in Spanish) and its English translation.21Opposition statement against Chilean Application No. 2187-2003 by La Asociacion Industrial De Laboratorios Farmaceuticos A.G. (in Spanish) and its English translation.22Opposition statement against Chilean Application No. 2187-2003 by Laboratorios Recalcine S.A. (in Spanish) and its English translation.23Opposition statement against Chilean Application No. 600-2007 by Asociacion Industrial de Laboratorios Farmaceuticos AG (in Spanish) and an English translation.24Opposition statement against Chilean Application No. 605-2007 by Asociacion Industrial de Laboratorios Farmaceuticos AG (in Spanish) and an English translation.25Opposition statement against Chilean Application No. 605-2007 by Laboratorios Recalcine S.A. (in Spanish) and an English translation.26Opposition statement against Ecuadorian Application No. SP 08-8239 by Asociacion de Laboratorios Farmaceuticos (ALAFAR) (in Spanish) and an English translation.27Opposition statement against Ecuadorian Application No. SP 08-8240 by Asociacion de Laboratorios Farmaceuticos (ALAFAR) (in Spanish) and an English translation.28Partial European Search Report for EP 04 02 4164, Aug. 9, 2006.29Roth (1998) "Efficacy and safety of tramadol HCL in breakthrough musculoskeletal pain attributed to osteoarthritis," J. Rheumatol 25:1358-63.30Ruoff (1999) "Strategies to Control Chronic Musculoskeletal Pain: A Guide to Drug Therapy," Consultant, 39:2773-81.31Ruoff, "Slowing the initial titration rate of tramadol improves tolerability," Pharmacotherapy 19(1):88-93 (Jan. 1999).32Saletu-Zyhlarz et al., "Confirmation of the Neurophysiologically Predicted Therapeutic Effects of Trazodone on Its Target Symptoms Depression, Anxiety and Insomnia by Postmarketing Clinical Studies with a Controlled-Release Formulation in Depressed Outpatients," Neuropsychobiology 2003; 48:194-208.33Search Report and Written Opinion for Intl. Application PCT/CA2006/001483, Jun. 4, 2007.34Search Report and Written Opinion for Intl. Application PCT/CA2006/001484, Jun. 8, 2007.35Stamer, "Impact of CYP2D6 genotype on postoperative tramadol analgesia," PAIN, 105(1-2):231-238 (2003).36Ultram � ER (tramadol HCI) Extended-Release Tablets Prescribing Information (4 pages).37Visavarungroj, N. et al., "Crosslinked Starch as a Disintegrating Agent," International Journal of Pharmaceutics 1990, vol. 62, No. 2/3, pp. 125-131.38Wilder-Smith et al. (2001) "Treatment of severe pain from osteoarthritis with slow-release tramadol or dihydrocodeine in combination with NSAID's: a randomized study comparing analgesia, antinociception and gastrointestinal effects," Pain 91:23-31.Referenced byCiting PatentFiling datePublication dateApplicantTitleWO2012072665A1Nov 30, 2011Jun 7, 2012Pharmaneuroboost N.V.Compositions comprising pipamperone and serotonin antagonist reuptake inhibitorsClassifications U.S. Classification424/489, 424/451, 424/464International ClassificationA61K9/20, A61K9/48, A61K9/14Cooperative ClassificationA61K9/2072, A61K9/2059, A61K9/2866, A61K31/16, A61K31/496, A61K9/2054, A61K9/205European ClassificationA61K9/20H6F, A61K31/496, A61K9/20H6F2, A61K9/20H6F4, A61K9/28H6F2, A61K9/20K, A61K31/16Legal EventsDateCodeEventDescriptionMay 9, 2014FPAYFee paymentYear of fee payment: 4Aug 29, 2013ASAssignmentOwner name: ANGELINI PHARMA INC., MARYLANDFree format text: MERGER;ASSIGNOR:ANGELINI LABOPHARM, LLC;REEL/FRAME:031107/0661Effective date: 20121205Jan 25, 2012ASAssignmentOwner name: ANGELINI LABOPHARM, LLC, NEW JERSEYFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LABOPHARM INC.;LABOPHARM EUROPE LIMITED;LABOPHARM (BARBADOS) LIMITED;REEL/FRAME:027589/0342Effective date: 20120120Dec 2, 2010ASAssignmentOwner name: LABOPHARM (BARBADOS) LIMITED, BARBADOSFree format text: CHANGE OF ADDRESS FOR ASSIGNEE;ASSIGNOR:LABOPHARM (BARBADOS) LIMITED;REEL/FRAME:025381/0533Effective date: 20100202Free format text: CHANGE OF ADDRESS FOR ASSIGNEE (SEE #2);ASSIGNOR:LABOPHARM (BARBADOS) LIMITED;REEL/FRAME:025381/0533Owner name: LABOPHARM (BARBADOS) LIMITED, BARBADOSFree format text: CHANGE OF ADDRESS FOR ASSIGNEE (SEE #2);ASSIGNOR:LABOPHARM (BARBADOS) LIMITED;REEL/FRAME:025381/0533Effective date: 20100202Feb 25, 2009ASAssignmentOwner name: LABOPHARM (BARBADOS) LIMITED - PARTIAL INTEREST (EFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LABOPHARM INC.;REEL/FRAME:022326/0246Effective date: 20080208Owner name: LABOPHARM EUROPE LIMITED - PARTIAL INTEREST (ENTIRFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LABOPHARM INC.;REEL/FRAME:022326/0246Effective date: 20080208Jun 12, 2007ASAssignmentOwner name: LABOPHARM, INC., QUEBECFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GERVAIS, SONIA;SMITH, DAMON;RAHMOUNI, MILOUD;AND OTHERS;REEL/FRAME:019415/0992;SIGNING DATES FROM 20070227 TO 20070424RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services